{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:26:03Z","timestamp":1744377963349,"version":"3.37.3"},"reference-count":35,"publisher":"Central Research Institute for Epidemiology","issue":"6","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["virusjour.crie.ru"],"crossmark-restriction":false},"short-container-title":["Problems of Virology"],"abstract":"<jats:p>Mucosal immunity is realized through a structural and functional system called mucose-associated lymphoid tissue (MALT). MALT is subdivided into parts (clusters) depending on their anatomical location, but they all have a similar structure: mucus layer, epithelial tissue, lamina propria and lymphoid follicles. Plasma cells of MALT produce a unique type of immunoglobulins, IgA, which have the ability to polymerize. In mucosal immunization, the predominant form of IgA is a secretory dimer, sIgA, which is concentrated in large quantities in the mucosa. Mucosal IgA acts as a first line of defense and neutralizes viruses efficiently at the portal of entry, preventing infection of epithelial cells and generalization of infection. To date, several mucosal antiviral vaccines have been licensed, which include attenuated strains of the corresponding viruses: poliomyelitis, influenza, and rotavirus. Despite the tremendous success of these vaccines, in particular, in the eradication of poliomyelitis, significant disadvantages of using attenuated viral strains in their composition are the risk of reactogenicity and the possibility of reversion to a virulent strain during vaccination. Nevertheless, it is mucosal vaccination, which mimics a natural infection, is able to induce a fast and effective immune response and thus help prevent and possibly stop outbreaks of many viral infections. Currently, a number of intranasal vaccines based on a new vector approach are successfully undergoing clinical trials. In these vaccines, the safe viral vectors are used to deliver protectively significant immunogens of pathogenic viruses. The most tested vector for intranasal vaccines is adenovirus, and the most significant immunogen is SARSCoV-2 S protein. Mucosal vector vaccines against human respiratory syncytial virus and human immunodeficiency virus type 1 based on Sendai virus, which is able to replicate asymptomatically in cells of bronchial epithelium, are also being investigated.<\/jats:p>","DOI":"10.36233\/0507-4088-82","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T12:06:34Z","timestamp":1641989194000},"page":"399-408","update-policy":"https:\/\/doi.org\/10.36233\/0372-9311-crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Mucosal immunity and vaccines against viral infections"],"prefix":"10.36233","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-4402","authenticated-orcid":false,"given":"S. S.","family":"Zainutdinov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8362-0314","authenticated-orcid":false,"given":"G. F.","family":"Sivolobova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-321X","authenticated-orcid":false,"given":"V. B.","family":"Loktev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0483","authenticated-orcid":false,"given":"G. V.","family":"Kochneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22004","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Terauchi Y., Sano K., Ainai A., Saito S., Taga Y., Ogawa-Goto K., et al. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated in\ufb02uenza vaccine administration. Hum. Vaccin. Immunother. 2018; 14(6): 1351\u201361. https:\/\/doi.org\/10.1080\/21645515.2018.1438791","DOI":"10.1080\/21645515.2018.1438791"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Russell M.W., Moldoveanu Z., Ogra P.L., Mestecky J. Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARSCoV-2 Infection. Front. Immunol. 2020; 11: 611337. https:\/\/doi.org\/10.3389\/fmmu.2020.611337","DOI":"10.3389\/fimmu.2020.611337"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Miquel-Clopes E.G., Bentley J.P., Stewart S.R., Carding S.R. Mucosal vaccines and technology. Clin. Exp. Immunol. 2019; 196(2):205\u201314. https:\/\/doi.org\/10.1111\/cei.13285","DOI":"10.1111\/cei.13285"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Travis C.R. As plain as the nose on your face: The case for a nasal (mucosal) route of vaccine administration for Covid-19 disease prevention. Front. Immunol. 2020; 11: 591897. https:\/\/doi.org\/10.3389\/fmmu.2020.591897","DOI":"10.3389\/fimmu.2020.591897"},{"key":"ref5","unstructured":"\u041b\u0443\u0441\u0441 \u041b.\u0412., \u0428\u0430\u0440\u0442\u0430\u043d\u043e\u0432\u0430 \u041d.\u0412., \u041d\u0430\u0437\u0430\u0440\u043e\u0432\u0430 \u0415.\u0412. \u0410\u043b\u043b\u0435\u0440\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0438 \u043d\u0435\u0430\u043b\u043b\u0435\u0440\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0440\u0438\u043d\u0438\u0442: \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0431\u0430\u0440\u044c\u0435\u0440\u043d\u044b\u0445 \u043c\u0435\u0442\u043e\u0434\u043e\u0432. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u0430\u044f \u0444\u0430\u0440\u043c\u0430\u043a\u043e\u0442\u0435\u0440\u0430\u043f\u0438\u044f. 2018; (17): 10\u20136."},{"key":"ref6","unstructured":"\u041a\u043e\u0437\u043b\u043e\u0432 \u0418.\u0413. \u041c\u0438\u043a\u0440\u043e\u0431\u0438\u043e\u0442\u0430, \u043c\u0443\u043a\u043e\u0437\u0430\u043b\u044c\u043d\u044b\u0439 \u0438\u043c\u043c\u0443\u043d\u0438\u0442\u0435\u0442 \u0438 \u0430\u043d\u0442\u0438\u0431\u0438\u043e\u0442\u0438\u043a\u0438: \u0442\u043e\u043d\u043a\u043e\u0441\u0442\u0438 \u0432\u0437\u0430\u0438\u043c\u043e\u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f. \u0420\u0443\u0441\u0441\u043a\u0438\u0439 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b. 2018; 26(8-1): 19\u201327."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ye L., Schnepf D., Staeheli P. Interferon-\u03bb orchestrates innate and adaptive mucosal immune responses. Nat. Rev. Immunol. 2019; 19(10): 614\u201325. https:\/\/doi.org\/10.1038\/s41577-019-0182-z","DOI":"10.1038\/s41577-019-0182-z"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Broggi A., Tan Y., Granucci F., Zanoni I. IFN-\u03bb suppresses intestinal in\ufb02ammation by non-translational regulation of neutrophil function. Nat. Immunol. 2017; 18(10): 1084\u201393. https:\/\/doi.org\/10.1038\/ni.3821","DOI":"10.1038\/ni.3821"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Fruitwala S., El-Naccache D.W., Chang T.L. Multifaceted immune functions of human defensins and underlying mechanisms. Semin. Cell Dev. Biol. 2019; 88: 163\u201372. https:\/\/doi.org\/10.1016\/j.semcdb.2018.02.023","DOI":"10.1016\/j.semcdb.2018.02.023"},{"key":"ref10","unstructured":"\u0429\u0443\u0431\u0435\u043b\u043a\u043e \u0420.\u0412., \u0417\u0443\u0439\u043a\u043e\u0432\u0430 \u0418.\u041d., \u0428\u0443\u043b\u044c\u0436\u0435\u043d\u043a\u043e \u0410.\u0415. \u041c\u0443\u043a\u043e\u0437\u0430\u043b\u044c\u043d\u044b\u0439 \u0438\u043c\u043c\u0443\u043d\u0438\u0442\u0435\u0442 \u0432\u0435\u0440\u0445\u043d\u0438\u0445 \u0434\u044b\u0445\u0430\u0442\u0435\u043b\u044c\u043d\u044b\u0445 \u043f\u0443\u0442\u0435\u0439. \u0418\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u044f. 2018; 39(1): 81\u20138. https:\/\/doi.org\/10.18821\/0206-4952-2018-39-1-81-88"},{"key":"ref11","unstructured":"\u0425\u0430\u0438\u0442\u043e\u0432 \u041c.\u0420., \u0418\u043b\u044c\u0438\u043d\u0430 \u041d.\u0418., \u041b\u0443\u0441\u0441 \u041b.\u0412., \u0411\u0430\u0431\u0430\u0445\u0438\u043d \u0410.\u0410. \u041c\u0443\u043a\u043e\u0437\u0430\u043b\u044c\u043d\u044b\u0439 \u0438\u043c\u043c\u0443\u043d\u0438\u0442\u0435\u0442 \u0440\u0435\u0441\u043f\u0438\u0440\u0430\u0442\u043e\u0440\u043d\u043e\u0433\u043e \u0442\u0440\u0430\u043a\u0442\u0430 \u0438 \u0435\u0433\u043e \u0440\u043e\u043b\u044c \u043f\u0440\u0438 \u043f\u0440\u043e\u0444\u0435\u0441\u0441\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u044b\u0445 \u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f\u0445. \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0430 \u044d\u043a\u0441\u0442\u0440\u0435\u043c\u0430\u043b\u044c\u043d\u044b\u0445 \u0441\u0438\u0442\u0443\u0430\u0446\u0438\u0439. 2017; 61(3): 8\u201324."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Coffey J.W., Gaiha G.D., Traverso G. Oral biologic delivery: advances towards oral subunit, DNA and mRNA vaccines and the potential for mass vaccination during pandemics. Annu. Rev. Pharmacol. Toxicol. 2021; 61: 517\u201340. https:\/\/doi.org\/10.1146\/annurev-pharmtox-030320-092348","DOI":"10.1146\/annurev-pharmtox-030320-092348"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kumar N., Arthur C.P., Ciferri C., Matsumoto M.L. Structure of the secretory immunoglobulin A core. Science. 2020; 367(6481):1008\u201314. https:\/\/doi.org\/10.1126\/science.aaz5807","DOI":"10.1126\/science.aaz5807"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hickey A.J., Garmise R.J. Dry powder nasal vaccines as an alternative to needle-based delivery. Crit. Rev. Ther. Drug Carr. Syst. 2009; 26(1): 1\u201327. https:\/\/doi.org\/10.1615\/critrevtherdrugcarriersyst.v26.i1.10","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i1.10"},{"key":"ref15","unstructured":"Bennett J.V., De Castro J.F., Valdespino-Gomez J.L., Garcia-Garcia M. de. L., Islas-Romero R., Echaniz-Aviles G., et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull. World Health Organ. 2002; 80(10):806\u201312. https:\/\/apps.who.int\/iris\/handle\/10665\/268635 (accessed November 14, 2021)."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hellfritzsc M., Scherlie R. Mucosal vaccination via the respiratory tract. Pharmaceutics. 2019; 11(8): 375. https:\/\/doi.org\/10.3390\/pharmaceutics11080375","DOI":"10.3390\/pharmaceutics11080375"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kozlowski P.A., Aldovini A. Mucosal vaccine approaches for prevention of HIV and SIV transmission. Curr. Immunol. Rev. 2019; 15(1): 102\u201322. https:\/\/doi.org\/10.2174\/1573395514666180605092054","DOI":"10.2174\/1573395514666180605092054"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Nyombayire J., Anzala O., Gazzard B., Karita E., Bergin F., Hayes P., et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus-vectored HIV type 1 gag vaccine: Induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis. 2017; 215(1): 95\u2013104. https:\/\/doi.org\/10.1093\/infdis\/jiw500","DOI":"10.1093\/infdis\/jiw500"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Sutter R.W., et al. Update on vaccine-derived polioviruses \u2013 worldwide, January 2017 \u2013 June 2018. MMWR Morb. Mortal. Wkly Rep. 2018; 67(42):1189\u201394. https:\/\/doi.org\/10.15585\/mmwr.mm6742a5","DOI":"10.15585\/mmwr.mm6742a5"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Dhere R., Yeolekar L., Kulkarni P., Menon R., Vaidya V., Ganguly M., et al. A pandemic in\ufb02uenza vaccine in India: From strain to sale within 12 months. Vaccine. 2011; 29(Suppl. 1): A16\u201321. https:\/\/doi.org\/10.1016\/j.vaccine.2011.04.119","DOI":"10.1016\/j.vaccine.2011.04.119"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Attenuated versus inactivated in\ufb02uenza vaccine in infants and young children. N. Engl. J. Med. 2007; 356(7): 685\u201396. https:\/\/doi.org\/10.1056\/NEJMoa065368","DOI":"10.1056\/NEJMoa065368"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 2001; 344(8): 564\u201372. https:\/\/doi.org\/10.1056\/NEJM200102223440804","DOI":"10.1056\/NEJM200102223440804"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Rotavirus vaccines WHO position paper: January 2013 \u2013 Recommendations. Vaccine. 2013; 31(52): 6170\u20131. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.037","DOI":"10.1016\/j.vaccine.2013.05.037"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Adderson E., Branum K., Sealy R.E., Jones B.G., Surman S.L., Penkert R. Safety and immunogenicity of an intranasal Sendai virus-based human parain\ufb02uenza virus type 1 vaccine in 3- to 6-yearold children. Clin. Vaccine Immunol. 2015; 22(3): 298\u2013303. https:\/\/doi.org\/10.1128\/CVI.00618-14","DOI":"10.1128\/CVI.00618-14"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Huang F.S., Bernstein D.I., Slobod K.S., Portner A., Takimoto T., Russell S.J., et al. Safety and immunogenicity of an intranasal Sendai virus-based vaccine for human parain\ufb02uenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum. Vaccin. Immunother. 2021; 17(2): 554\u20139. https:\/\/doi.org\/10.1080\/21645515.2020.1779517","DOI":"10.1080\/21645515.2020.1779517"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Tasker S., O\u2019Rourke A.N., Suyundikov A., Booth P.-G.J., Bart S., Krishnan V., et al. Safety and immunogenicity of a novel intranasal in\ufb02uenza vaccine (NasoVAX): A phase 2 randomized, controlled trial. Vaccines. 2021; 9(3): 224. https:\/\/doi.org\/10.3390\/vaccines9030224","DOI":"10.3390\/vaccines9030224"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lund F.E., Randall T.D. Scent of a vaccine. Science. 2021; 373(6553): 397\u20139. https:\/\/doi.org\/10.1126\/science.abg9857","DOI":"10.1126\/science.abg9857"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"King R.G., Silva-Sanchez A., Peel J.N., Botta D., Dickson A.M., Pinto A.K., et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge. Vaccines (Basel). 2021; 9(8): 881. https:\/\/doi.org\/10.3390\/vaccines9080881","DOI":"10.3390\/vaccines9080881"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Hassan A.O., Kafai N.M., Dmitriev I.P., Fox J.M., Smith B.K., Harvey I.B., et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020; 183(1): 169\u201384.E13. https:\/\/doi.org\/10.1016\/j.cell.2020.08.026","DOI":"10.1016\/j.cell.2020.08.026"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Hassan A.O., Shrihari S., Gorman M.J., Ying B., Yuan D., Raju S., et al. An intranasal vaccine durably protects against SARSCoV-2 variants in mice. Cell Rep. 2021; 36(4): 109452. https:\/\/doi.org\/10.1016\/j.celrep.2021.109452","DOI":"10.1016\/j.celrep.2021.109452"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hassan A.O., Feldmann F., Zhao H., Curiel D.T., Okumura A., Tang-Huau T.L., et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep. Med. 2021; 2(4): 100230. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100230","DOI":"10.1016\/j.xcrm.2021.100230"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Doremalen N., Purushotham J.N., Schulz J.E., Holbrook M.G., Bushmaker T., Carmody F., et al. Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARSCoV-2 D614G challenge in preclinical models. Sci. Transl. Med. 2021; 13(607): eabh0755. https:\/\/doi.org\/10.1126\/scitranslmed.abh0755","DOI":"10.1126\/scitranslmed.abh0755"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Gallo O., Locatello L.G., Mazzoni A., Novelli L., Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2020; 14(2): 305\u201316. https:\/\/doi.org\/10.1038\/s41385-020-00359-2","DOI":"10.1038\/s41385-020-00359-2"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Moreno-Fierros L., Garc\u00eda-Silva I., Rosales-Mendoza S. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Expert. Opin. Biol. Ther. 2020; 20(8): 831\u20136. https:\/\/doi.org\/10.1080\/14712598.2020.1767062","DOI":"10.1080\/14712598.2020.1767062"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Mudgal R., Nehul S., Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum. Vaccin. Immunother. 2020; 16(12): 2921\u201331. https:\/\/doi.org\/10.1080\/21645515.2020.1805992","DOI":"10.1080\/21645515.2020.1805992"}],"container-title":["Problems of Virology"],"original-title":[],"link":[{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/573\/350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/573\/350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:59:17Z","timestamp":1732528757000},"score":1,"resource":{"primary":{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/view\/573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12,9]]}},"URL":"https:\/\/doi.org\/10.36233\/0507-4088-82","relation":{},"ISSN":["2411-2097","0507-4088"],"issn-type":[{"type":"electronic","value":"2411-2097"},{"type":"print","value":"0507-4088"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}